Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PROSTATE CANCER

AR variants: lost in translation to clinical practice?

Nature Reviews Urology volume 16, pages 451–452 (2019)Cite this article

Subjects

The concept that resistance against androgen receptor (AR) signalling inhibitors is explained by AR variants (ARVs) has spread as a seductive meme. However, two problems have delayed the translation of these findings to clinical practice: the complexity of the mechanism of action and the challenging development of clinical decision-making tools involving ARVs.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: ARVs in prostate cancer.

References

  1. Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028–1038 (2014).

    Article  Google Scholar 

  2. Miyamoto, D. T. et al. RNA-seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science 349, 1351–1356 (2015).

    Article  CAS  Google Scholar 

  3. Alen, P. et al. The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol. Cell. Biol. 19, 6085–6097 (1999).

    Article  CAS  Google Scholar 

  4. Cato, L. et al. ARv7 represses tumor-suppressor genes in castration-resistant prostate cancer. Cancer Cell 35, 401–413 (2019).

    Article  CAS  Google Scholar 

  5. Armstrong, A. J. et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. J. Clin. Oncol. 37, 1120–1129 (2019).

    Article  Google Scholar 

  6. To, S. Q. et al. Expression of androgen receptor splice variant 7 or 9 in whole blood does not predict response to androgen-axis-targeting agents in metastatic castration-resistant prostate cancer. Eur. Urol. 73, 818–821 (2018).

    Article  CAS  Google Scholar 

  7. Luo, J. et al. Role of androgen receptor variants in prostate cancer: report from the 2017 Mission Androgen Receptor Variants Meeting. Eur. Urol. 73, 715–723 (2018).

    Article  Google Scholar 

  8. Bernemann, C. et al. Comparative analysis of AR variant AR-V567es mRNA detection systems reveals eminent variability and questions the role as a clinical biomarker in prostate cancer. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-18-4276 (2019).

    Article  Google Scholar 

  9. Sharp, A. et al. Clinical utility of circulating tumour cell androgen receptor splice variant-7 status in metastatic castration-resistant prostate cancer. Eur. Urol. https://doi.org/10.1016/j.eururo.2019.04.006 (2019).

  10. Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl Acad. Sci. USA https://doi.org/10.1073/pnas.1902651116 (2019).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium

    Florian Handle & Frank Claessens

Authors
  1. Florian Handle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank Claessens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank Claessens.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Handle, F., Claessens, F. AR variants: lost in translation to clinical practice?. Nat Rev Urol 16, 451–452 (2019). https://doi.org/10.1038/s41585-019-0204-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-019-0204-4

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer